Arvinas
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Connecticut, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
395 Winchester Ave, New Haven, Connectic...Phone Number
(203) 535-1456Website
www.arvinas.comRevenue
$316.7 MillionStock Symbol
ARVNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Arvinas
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its proprietary PROTAC® platform. The company focuses on discovering and developing innovative medicines for cancer, neurology, and other serious diseases by selectively degrading disease-causing proteins. Its research-driven approach aims to expand treatment possibilities for patients with difficult-to-treat conditions.Explore more
Arvinas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arvinas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Arvinas is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Arvinas
Click to see if Arvinas had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Arvinas has new funding data
Product Launch: Get notified when Arvinas launches new products
Check if Arvinas has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Arvinas recently announced quarterly report
Website visits: Recent activity has been detected on your website
Arvinas, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Arvinas as Masked Content
Find more new buyers
Compare Similar Companies to Arvinas
Compare insights from companies similar to Arvinas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$35M
51-200
Public
$425M
2015
Kendra AdamsChief Financial Officer & Head Corporate Affairs & Principal Accounting Officer
Company Profile Activity
Activity Insights
Arvinas is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arvinas is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arvinas.
Arvinas financials insights
Gather financial insights about Arvinas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Corporate Investment
$3.3M
Series A
$15M
2015
Series B
$41.6M
2018
Series C
$55M
Stock Offering
$120M
Arvinas Tech Stack
A closer look at the technologies used by Arvinas
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Person-Based
Medical Research
Person-Based
Accounting
Person-Based
Pharmaceuticals, Corporate Strategy
Arvinas News & Media
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant toArvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals –Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arvinas
Sign Up For FreeTo access detailed company insights
Arvinas is a clinical-stage biotechnology company pioneering targeted protein degradation therapies through its proprietary PROTAC® platform. The company focuses on discovering and developing innovative medicines for cancer, neurology, and other serious diseases by selectively degrading disease-causing proteins. Its research-driven approach aims to... Read More
